Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence

This article was originally published in The Pink Sheet Daily

Executive Summary

Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.

You may also be interested in...



Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says

This time, the agency may be ready to agree with its advisory committee.

Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Sen. Alexander and others remain optimistic as several holds and a filibuster threat emerge.

Vaccines In Brief: ACIP Recommends Valneva's Chikungunya Shot For Travelers, Lab Workers

CDC’s advisory committee also approves a VFC program update allowing for the rare, off-label use of tetanus toxoid- and diphtheria toxoid-containing vaccine in young children, and plans to move up timing of its COVID-19 vaccine recommendations for the 2024-2025 formulation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel